Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Account Payables
Amounts the company owes suppliers for goods and services received.
Maze Therapeutics, Inc.NASDAQ: MAZE
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 66.9% from a year ago
Account payables stood at $4.01M at the end of Q1 FY2026, up 66.9% from a year earlier and up 123.7% from the prior quarter. Over 3 fiscal years it compounded at +4.2% a year.
Context
- Account payables amounted to 1.0% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +66.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 1.79M USD
- Year-over-year change
- -7.5%
- 3-year CAGR
- +4.2%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.79M | -7.5% |
| FY2024 | 2024-12-31 | 1.94M | -4.0% |
| FY2023 | 2023-12-31 | 2.02M | +27.4% |
| FY2022 | 2022-12-31 | 1.59M | — |
Account Payables vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +66.9% is the 4th highest of 8, against a peer median of +52.6%.
- Account payables amounts to 1.0% of total assets for MAZE, versus a peer median of 1.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $40.45M USD | +52.6% | +18.6% | 1.2% | |
| Mar 2026 | $28.2M USD | +105.5% | +21.0% | 5.6% | |
| Dec 2025 | €26.01M EUR | -20.9% | +10.3% | 10.4% | |
| Sep 2026 | $15.28M USD | -16.1% | +12.8% | 1.8% | |
SEPNSepterna, Inc. | Sep 2026 | $6.96M USD | +86.7% | +49.6% | 1.1% |
| Mar 2026 | $4.01M USD | +66.9% | +4.2% | 1.0% | |
| Mar 2026 | $3.29M USD | +118.5% | +26.2% | 6.2% | |
BIOABioAge Labs, Inc. | Mar 2026 | $3.07M USD | -23.1% | +5.8% | 0.8% |
| Peer median (excluding MAZE) | — | +52.6% | +18.6% | 1.8% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.